FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294363651> ?p ?o ?g. }

• W4294363651 abstract "Sarcopenia gained importance in the evaluation of patients with chronic respiratory diseases, including idiopathic pulmonary fibrosis (IPF), since it may impact negatively on clinical outcomes.Aim of this study is to evaluate the prevalence and factors associated with sarcopenia, defined according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) 2019 definition, and to evaluate the prevalence of the single criteria that define the EWGSOP2 definition (muscle strength, muscle quantity and physical performance), in a cohort of consecutive patients with IPF prospectively followed up in 9 hospitals in Northern Italy between December 2018 and May 2021.Enrolled patients underwent an extensive pulmonary and nutritional assessment, including bioelectrical impedance analysis, dynamometry and 4-m gait speed test, both at IPF diagnosis and at 6-month follow-up.Out of the 83 patients (81% males, mean age 72.5 years) with IPF at disease diagnosis enrolled in the study, 19 (22.9%) showed sarcopenia, including 2 (2.4%) with severe sarcopenia, 5 (6.0%) with confirmed sarcopenia and 12 (14.5%) with probable sarcopenia. Sarcopenia was associated with a significantly higher severity of the disease and sedentary lifestyle, while no differences were observed in regards to body mass index, history of weight loss and comorbidities between patients with and without sarcopenia. Out of the 64 patients without sarcopenia at baseline, 16 cases showed alteration of muscle quantity and/or physical performance. In the 51 patients with complete data at 6-month follow-up, there were no cases of severe sarcopenia, 1 case (2.0%) showed confirmed sarcopenia, while the prevalence of probable sarcopenia was 19.6% (10 cases). No differences in regards to antifibrotic treatment received and onset of gastrointestinal side effects were observed between patients with and without sarcopenia at follow-up.The prevalence of sarcopenia in patients with IPF both at diagnosis and at 6-month follow-up was low but not negligible and was associated with higher severity of the disease and sedentary lifestyle. In IPF patients, a comprehensive diagnostic work-up including all the criteria defining the EWGSOP2 definition might be more useful than a series testing for prompt recognition of nutritional and physical performance abnormalities." @default.
• W4294363651 created "2022-09-03" @default.
• W4294363651 creator A5001932904 @default.
• W4294363651 creator A5004445358 @default.
• W4294363651 creator A5006196984 @default.
• W4294363651 creator A5007136932 @default.
• W4294363651 creator A5008263843 @default.
• W4294363651 creator A5014898634 @default.
• W4294363651 creator A5015154982 @default.
• W4294363651 creator A5017334540 @default.
• W4294363651 creator A5017716537 @default.
• W4294363651 creator A5021616542 @default.
• W4294363651 creator A5026887019 @default.
• W4294363651 creator A5032963015 @default.
• W4294363651 creator A5036008159 @default.
• W4294363651 creator A5038572083 @default.
• W4294363651 creator A5040901324 @default.
• W4294363651 creator A5041414882 @default.
• W4294363651 creator A5044878653 @default.
• W4294363651 creator A5046351090 @default.
• W4294363651 creator A5046959234 @default.
• W4294363651 creator A5055404078 @default.
• W4294363651 creator A5060382649 @default.
• W4294363651 creator A5061704721 @default.
• W4294363651 creator A5067283536 @default.
• W4294363651 creator A5067596556 @default.
• W4294363651 creator A5071626680 @default.
• W4294363651 creator A5076480220 @default.
• W4294363651 creator A5079510272 @default.
• W4294363651 creator A5081483998 @default.
• W4294363651 creator A5084563383 @default.
• W4294363651 creator A5087327035 @default.
• W4294363651 creator A5087380679 @default.
• W4294363651 date "2022-09-03" @default.
• W4294363651 modified "2023-10-15" @default.
• W4294363651 title "Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach" @default.
• W4294363651 cites W2149295929 @default.
• W4294363651 cites W2155416296 @default.
• W4294363651 cites W2559934887 @default.
• W4294363651 cites W2897513125 @default.
• W4294363651 cites W2924524131 @default.
• W4294363651 cites W2936452197 @default.
• W4294363651 cites W2938976468 @default.
• W4294363651 cites W3006016252 @default.
• W4294363651 cites W3016295308 @default.
• W4294363651 cites W3081708742 @default.
• W4294363651 cites W3088702810 @default.
• W4294363651 cites W3197019270 @default.
• W4294363651 cites W3212155451 @default.
• W4294363651 cites W4220783647 @default.
• W4294363651 doi "https://doi.org/10.1186/s12931-022-02159-7" @default.
• W4294363651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36057620" @default.
• W4294363651 hasPublicationYear "2022" @default.
• W4294363651 type Work @default.
• W4294363651 citedByCount "6" @default.
• W4294363651 countsByYear W42943636512023 @default.
• W4294363651 crossrefType "journal-article" @default.
• W4294363651 hasAuthorship W4294363651A5001932904 @default.
• W4294363651 hasAuthorship W4294363651A5004445358 @default.
• W4294363651 hasAuthorship W4294363651A5006196984 @default.
• W4294363651 hasAuthorship W4294363651A5007136932 @default.
• W4294363651 hasAuthorship W4294363651A5008263843 @default.
• W4294363651 hasAuthorship W4294363651A5014898634 @default.
• W4294363651 hasAuthorship W4294363651A5015154982 @default.
• W4294363651 hasAuthorship W4294363651A5017334540 @default.
• W4294363651 hasAuthorship W4294363651A5017716537 @default.
• W4294363651 hasAuthorship W4294363651A5021616542 @default.
• W4294363651 hasAuthorship W4294363651A5026887019 @default.
• W4294363651 hasAuthorship W4294363651A5032963015 @default.
• W4294363651 hasAuthorship W4294363651A5036008159 @default.
• W4294363651 hasAuthorship W4294363651A5038572083 @default.
• W4294363651 hasAuthorship W4294363651A5040901324 @default.
• W4294363651 hasAuthorship W4294363651A5041414882 @default.
• W4294363651 hasAuthorship W4294363651A5044878653 @default.
• W4294363651 hasAuthorship W4294363651A5046351090 @default.
• W4294363651 hasAuthorship W4294363651A5046959234 @default.
• W4294363651 hasAuthorship W4294363651A5055404078 @default.
• W4294363651 hasAuthorship W4294363651A5060382649 @default.
• W4294363651 hasAuthorship W4294363651A5061704721 @default.
• W4294363651 hasAuthorship W4294363651A5067283536 @default.
• W4294363651 hasAuthorship W4294363651A5067596556 @default.
• W4294363651 hasAuthorship W4294363651A5071626680 @default.
• W4294363651 hasAuthorship W4294363651A5076480220 @default.
• W4294363651 hasAuthorship W4294363651A5079510272 @default.
• W4294363651 hasAuthorship W4294363651A5081483998 @default.
• W4294363651 hasAuthorship W4294363651A5084563383 @default.
• W4294363651 hasAuthorship W4294363651A5087327035 @default.
• W4294363651 hasAuthorship W4294363651A5087380679 @default.
• W4294363651 hasBestOaLocation W42943636511 @default.
• W4294363651 hasConcept C126322002 @default.
• W4294363651 hasConcept C1862650 @default.
• W4294363651 hasConcept C188816634 @default.
• W4294363651 hasConcept C2776214593 @default.
• W4294363651 hasConcept C2777714996 @default.
• W4294363651 hasConcept C2778341716 @default.
• W4294363651 hasConcept C2780221984 @default.
• W4294363651 hasConcept C33872192 @default.
• W4294363651 hasConcept C71924100 @default.
• W4294363651 hasConcept C72563966 @default.
• W4294363651 hasConceptScore W4294363651C126322002 @default.

• next